Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AEMD NASDAQ:FEMY NASDAQ:ICU NASDAQ:MBAI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEMDAethlon Medical$1.92+1.4%$2.20$1.36▼$27.40$4.48M1.491.68 million shs85,749 shsFEMYFemasys$4.04$7.17$3.77▼$22.20$12.20M-2.23133,503 shs43,803 shsICUSeaStar Medical$3.12$3.80$2.07▼$12.50$12.47M-1.0586,775 shs42,442 shsMBAICheck-Cap$1.43$1.61$0.59▼$3.92$10.42M0.5965,216 shs54,944 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEMDAethlon Medical+0.37%+0.89%-4.86%-11.25%-88.98%FEMYFemasys-3.58%-15.48%-43.67%-63.60%-77.05%ICUSeaStar Medical+1.96%+14.29%-19.79%+39.91%-68.16%MBAICheck-Cap+5.15%+4.38%-20.99%-13.07%+142,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEMDAethlon Medical$1.92+1.4%$2.20$1.36▼$27.40$4.48M1.491.68 million shs85,749 shsFEMYFemasys$4.04$7.17$3.77▼$22.20$12.20M-2.23133,503 shs43,803 shsICUSeaStar Medical$3.12$3.80$2.07▼$12.50$12.47M-1.0586,775 shs42,442 shsMBAICheck-Cap$1.43$1.61$0.59▼$3.92$10.42M0.5965,216 shs54,944 shs7 Stocks That Will Be Magnificent in 2026Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEMDAethlon Medical+0.37%+0.89%-4.86%-11.25%-88.98%FEMYFemasys-3.58%-15.48%-43.67%-63.60%-77.05%ICUSeaStar Medical+1.96%+14.29%-19.79%+39.91%-68.16%MBAICheck-Cap+5.15%+4.38%-20.99%-13.07%+142,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAEMDAethlon Medical 1.50ReduceN/AN/AFEMYFemasys 2.50Moderate Buy$106.672,540.26% UpsideICUSeaStar Medical 2.00Hold$8.00156.41% UpsideMBAICheck-Cap 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest AEMD, ICU, FEMY, and MBAI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/3/2026FEMYFemasys Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/18/2026FEMYFemasys Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/14/2026ICUSeaStar Medical Maxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$6.00 ➝ $8.005/1/2026FEMYFemasys Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/24/2026MBAICheck-Cap Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026ICUSeaStar Medical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026AEMDAethlon Medical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 6/19/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAEMDAethlon MedicalN/AN/AN/AN/A$3.11 per shareN/AFEMYFemasys$2.29M5.33N/AN/A$2.01 per share2.01ICUSeaStar Medical$1.23M10.15N/AN/A$2.75 per share1.13MBAICheck-CapN/AN/A$0.57 per share2.52$0.47 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAEMDAethlon Medical-$7.15M-$14.69N/AN/AN/AN/A-137.73%-105.87%8/12/2026 (Estimated)FEMYFemasys-$18.63M-$5.40N/AN/AN/A-521.97%-258.08%-73.72%8/12/2026 (Estimated)ICUSeaStar Medical-$12.15M-$4.80N/AN/AN/A-828.62%-146.29%-96.48%8/12/2026 (Estimated)MBAICheck-Cap$4.14M-$2.77N/AN/AN/AN/AN/AN/AN/ALatest AEMD, ICU, FEMY, and MBAI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026ICUSeaStar Medical-$0.8250-$0.90-$0.0750-$0.90$0.44 million$0.50 million5/8/2026Q1 2026FEMYFemasys-$1.3334$0.0980+$1.4314N/A$0.77 million$0.42 million3/31/2026Q4 2025FEMYFemasys-$1.6666-$0.20+$1.4666-$0.01$1.06 million$0.81 million3/25/2026Q4 2025ICUSeaStar Medical-$0.97-$0.80+$0.17-$0.80$0.22 million$0.42 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAEMDAethlon MedicalN/AN/AN/AN/AN/AFEMYFemasysN/AN/AN/AN/AN/AICUSeaStar MedicalN/AN/AN/AN/AN/AMBAICheck-CapN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAEMDAethlon MedicalN/A3.853.85FEMYFemasys0.533.911.98ICUSeaStar MedicalN/A2.732.71MBAICheck-CapN/A0.050.05Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAEMDAethlon Medical1.99%FEMYFemasys65.27%ICUSeaStar Medical1.69%MBAICheck-Cap1.07%Insider OwnershipCompanyInsider OwnershipAEMDAethlon Medical0.71%FEMYFemasys7.75%ICUSeaStar Medical0.70%MBAICheck-Cap0.48%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAEMDAethlon Medical102.37 million2.35 millionNo DataFEMYFemasys303.02 million2.79 millionNot OptionableICUSeaStar Medical24.00 million3.97 millionNot OptionableMBAICheck-Cap807.29 million7.25 millionN/AAEMD, ICU, FEMY, and MBAI HeadlinesRecent News About These CompaniesComparing Check-Cap (NASDAQ:MBAI) & Medline (NASDAQ:MDLN)June 18 at 4:21 AM | americanbankingnews.comCheck-Cap Presents MBody AI Robotics Platform at Planet MicroCap and Northland Growth Conferences in June 2026June 10, 2026 | markets.businessinsider.comCheck-Cap Ltd MBAIMay 28, 2026 | morningstar.comMCheck-Cap Presents MBody AI Robotics Platform at Miami Investor SummitMay 26, 2026 | finance.yahoo.comCheck-Cap ($MBAI) Advances NASDAQ Listing for MBody AI MergerApril 30, 2026 | markets.businessinsider.comMBody AI Corp. Expands Fortune 500 Deployment, Advancing National Robotics RolloutMarch 26, 2026 | markets.businessinsider.comMBody AI and Check Cap Ltd. ($MBAI) Submit Nasdaq Listing Application for Merger CloseFebruary 24, 2026 | markets.businessinsider.comCheck-Cap Advances MBody AI Merger with F-1 Filing and MBody AI Audited FinancialsFebruary 2, 2026 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThe Case for Intel Over Pure-Play Quantum FirmsBy Nathan Reiff | June 9, 2026As Small-Cap Outperformance Continues, These 2 ETFs Provide ExposureBy Jessica Mitacek | May 21, 2026Deere Beats Q2 Estimates, But Ag Weakness Weighs on OutlookBy Chris Markoch | May 22, 2026Why 1 Little-Known ETF Is Riding the AI Chip ShortageBy Nathan Reiff | June 2, 2026Is Lennar Finally Turning the Corner After Its Housing Slump?By Leo Miller | June 16, 2026AEMD, ICU, FEMY, and MBAI Company DescriptionsAethlon Medical NASDAQ:AEMD$1.92 +0.03 (+1.43%) Closing price 06/18/2026 03:59 PM EasternExtended Trading$1.94 +0.02 (+1.20%) As of 06/18/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Aethlon Medical, Inc., a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses and use in organ transplantation. The company was incorporated in 1999 and is based in San Diego, California.Femasys NASDAQ:FEMY$4.04 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$4.16 +0.13 (+3.09%) As of 06/18/2026 06:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination. It also develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. The company offers its products to reproductive endocrinologists for infertility products, obstetrics-gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.SeaStar Medical NASDAQ:ICU$3.12 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$3.11 -0.01 (-0.32%) As of 06/18/2026 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.SeaStar Medical Holding Corporation, a medical device company, develops a platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers inflammatory response to fend off infections and repair damaged tissue in the body. It is also developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure; myocardial stunning in end stage renal disease; and hepatorenal syndrome. The company is headquartered in Denver, Colorado.Check-Cap NASDAQ:MBAI$1.43 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$1.46 +0.04 (+2.45%) As of 06/18/2026 07:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation. The company was incorporated in 2004 and is based in Isfiya, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore Aehr Spikes on New Order, But Has Stock Gotten Ahead of Itself? Why Kroger’s Pullback Could Be a Gift for Patient Investors Credo Technologies Accelerates AI—Its Stock Price Will Follow Why Rocket Lab’s Nasdaq-100 Moment Could Change the Story Why Palantir’s Google Cloud Deal Could Change the Debate VMware: Broadcom's Second Biggest Business Set to Accelerate American Eagle’s Q1 Beat Leaves Investors With a Bigger Question Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
